Last reviewed · How we verify
Roxacin (ROXITHROMYCIN)
Roxithromycin works by binding to the bacterial ribosome and inhibiting protein synthesis.
Roxithromycin, also known as Roxacin, is a small molecule antibiotic drug that targets the motilin receptor. It belongs to the macrolide class of antibiotics and is used to treat various bacterial infections. However, its commercial status and approved indications are unknown. As a macrolide antibiotic, roxithromycin works by inhibiting protein synthesis in bacteria, ultimately leading to their death. Further information on its pharmacokinetics and safety profile is needed.
At a glance
| Generic name | ROXITHROMYCIN |
|---|---|
| Drug class | roxithromycin |
| Target | Motilin receptor, 50S ribosomal protein L10, Alpha-1B adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins to harm you. Roxithromycin is like a key that locks the bacterial factory, preventing it from making proteins and ultimately killing the bacteria.
Approved indications
Common side effects
- Jaundice
- Drug-induced liver injury
- Drug interaction
- Myopathy
Key clinical trials
- Bioequivalence Study of Two Roxithromycin Tablets in Healthy Subjects (PHASE1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis (PHASE3)
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication. (PHASE4)
- Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) (NA)
- Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome (PHASE4)
- Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)
- Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Roxacin CI brief — competitive landscape report
- Roxacin updates RSS · CI watch RSS